Safety of sildenafil in infants

Pediatric Critical Care Medicine

Volumn 15, Issue 4, 2014, Pages 362-368

  Samiee Zafarghandy, Samira ^a   Smith, P Brian ^b,c   Van Den Anker, Johannes N ^a,d,e  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Adverse events; Infants; Off label; Pulmonary hypertension; Safety; Sildenafil

Indexed keywords

CYTOCHROME P450 3A4; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CASE REPORT; CASE STUDY; CHILD; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; EYE DISEASE; FEVER; HEADACHE; HEARING IMPAIRMENT; HUMAN; INFANT; INFORMATION RETRIEVAL; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; PEDIATRICS; PERSISTENT PULMONARY HYPERTENSION; PHARMACODYNAMICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETINA HEMORRHAGE; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD CLOTTING DISORDER; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION, PULMONARY; MORTALITY; NERVOUS SYSTEM; NEWBORN;

BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; EYE DISEASES; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; NERVOUS SYSTEM; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 84900524392     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0000000000000077     Document Type: Review

References (64)

1. Center for Drug Evaluation and Research: NDA 020895 VIAGRA® (Sildenafil Citrate) Tablets: Clinical Pharmacology/Biopharmaceutics Review. Rockville, MD, Department of Health and Human Services, US Food and Drug Administration, 1998
2. Omori K, Kotera J: Overview of PDEs and their regulation. Circ Res 2007; 100:309-327
3. Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5:689-702 (Pubitemid 44151606)
4. Center for Drug Evaluation and Research: NDA 022473 REVATIO® (Sildenafil) Injections: Clinical Pharmacology/Biopharmaceutics Review. Rockville, MD, Department of Health and Human Services, US Food and Drug Administration, 2005
5. Barst RJ, Ivy DD, Gaitan G, et al: A randomized, double-blind, placebo- controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125:324-33
6. Gupta M, Kovar A, Meibohm B: The clinical pharmacokinetics of phosphodiesterase- 5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45:987-1003 (Pubitemid 41192358)
7. Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53:5-12
8. Muirhead GJ, Rance DJ, Walker DK, et al: Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol 2002; 53:13S-20S
9. Mukherjee A, Dombi T, Wittke B, et al: Population pharmacokinetics of sildenafil in term neonates: Evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009; 85:56-63
10. Mehrotra N, Gupta M, Kovar A, et al: The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19:253-264 (Pubitemid 46701452)
11. EMEA: Revatio: Scientific Discussion & Summary of Product Characteristics. London, UK, European Medicine Agency, 2011
12. Warrington JS, Shader RI, von Moltke LL, et al: In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000; 28:392-397
13. Muirhead GJ, Wilner K, Colburn W, et al: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol 2002; 53:21S-30S
14. Vachiery JL, Huez S, Gillies H, et al: Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 2011; 71:289-292
15. Ballard SA, Gingell CJ, Tang K, et al: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159:2164-2171 (Pubitemid 29190800)
16. Cote RH: Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5. Int J Impot Res 2004; 16(Suppl 1):S28-S33
17. Lacroix D, Sonnier M, Moncion A, et al: Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247:625-634 (Pubitemid 27308642)
18. Koukouritaki SB, Manro JR, Marsh SA, et al: Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308:965-974 (Pubitemid 38263972)
19. Ahsman MJ, Witjes BC, Wildschut ED, et al: Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed 2010; 95:F109-F114
20. Duke University; University of North Carolina, Chapel Hil: Pharmacokinetics of sildenafil in premature infants. ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine (US), 2000. NLM Identifier: NCT01670136. Available at: http://clinicaltrials.gov/show/ NCT01670136. Accessed October 23, 2013
21. Galié N, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. NEJM 2006; 354:2148-2157
22. Huddleston AJ, Knoderer CA, Morris JL, et al: Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol 2009; 30:871-882
23. Sola A, Baquero H: [Oral sildenafil in neonatal medicine: "Tested in adults also used in neonates"]. An Pediatr (Barc) 2007; 66:167-176
24. Steinhorn RH, Kinsella JP, Pierce C, et al: Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155:841-847.e1
25. Shah PS, Ohlsson A: Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011; 1-35
26. Herrea Torres R, Concha Gonzalez EP, Holberto Castillo J, et al: Sildenafil oral como alternativa en el tratamiento de recien nacidos con hipertension pulmonar persistente. Revista Mexicana de Pediatria 2006; 73:159-163
27. Baquero H, Soliz A, Neira F, et al: Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006; 117:1077-1083 (Pubitemid 46071498)
28. Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, et al: The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol 2010; 27:225-230
29. Zhang R, Wang Y, Zhang L, et al: Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002; 33:2675-2680 (Pubitemid 35266440)
30. Monastero R, Pipia C, Camarda LK, et al: Intracerebral haemorrhage associated with sildenafil citrate. J Neurol 2001; 248:141-142 (Pubitemid 32245426)
31. Arnavaz A, Aurich A, Weissenborn K, et al: Effect of sildenafil (Viagra) on cerebral blood flow velocity: A pilot study. Psychiatry Res 2003; 122:207-209 (Pubitemid 36412196)
32. Kruuse C, Thomsen LL, Jacobsen TB, et al: The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22:1124-1131 (Pubitemid 35006805)
33. Nagdyman N, Fleck T, Bitterling B, et al: Influence of intravenous sildenafil on cerebral oxygenation measured by near-infrared spectroscopy in infants after cardiac surgery. Pediatr Res 2006; 59:462-465 (Pubitemid 43740089)
34. Pfizer; Pediatric Intensive Care, Great Ormond Street Hospital: A follow up investigation for patients completing study A1481276 to investigate developmental progress 12 and 24 months following completion of sildenafil treatment. ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine (US), 2000. NLM Identifier: NCT01801982. Available at: http://clinicaltrials.gov/show/NCT01801982. Accessed October 23, 2013
35. Pfizer; University Hospital Women and Infants Center: A multi-centre, randomized, placebo-controlled, double-blind, two-armed, parallel group study to evaluate efficacy and safety of IV sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure and at risk for PPHN, with long term follow-up investigation of developmental progress 12 and 24 months after completion of study treatment. ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine (US), 2000. NLM Identifier: NCT01720524. Available at: http://clinicaltrials.gov/show/ NCT01720524. Accessed October 23, 2013
36. Samada K, Shiraishi H, Aoyagi J, et al: Cerebral hemorrhage associated with sildenafil (Revatio) in an infant. Pediatr Cardiol 2009; 30:998-999
37. Buxton N, Flannery T, Wild D, et al: Sildenafil (Viagra)-induced spontaneous intracerebral haemorrhage. Br J Neurosurg 2001; 15:347-349 (Pubitemid 32889436)
38. March CS, Marden B, Newsom R: Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 2004; 88: 306-307
39. Kehat R, Bonsall DJ, North R, et al: Ocular findings of oral sildenafil use in term and near-term neonates. J AAPOS 2010; 14: 159-162
40. Cheitlin MD, Hutter M, Brindis RG, et al: Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99:168-177 (Pubitemid 29035976)
41. Vassalos A, Peng E, Young D, et al: Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: A randomised trial in children undergoing cardiac surgery. Anaesthesia 2011; 66:472-480
42. Limjoco J, Paquette L, Ramanathan R, et al: Changes in mean arterial blood pressure during sildenafil use in neonates with meconium aspiration syndrome or sepsis. Am J Ther 2013; 23:2-8
43. Afif F, EL-Khuffash AF, Jain A, et al: Enhancing the care of preterm infants undergoing surgical ligation of a patent ductusarteriosus. Neonatology Today 2011; 6:1-8
44. Kleinsasser A, Loeckinger A, Hoermann C, et al: Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 2001; 163:339-343 (Pubitemid 32158509)
45. Schulze-Neick I, Hartenstein P, Li J, et al: Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108(Suppl 1):II167-II173
46. Gudmundsdóttir IJ, McRobbie SJ, Robinson SD, et al: Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys Res Commun 2005; 337:382-385 (Pubitemid 41393806)
47. Halcox JP, Nour KR, Zalos G, et al: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40:1232-1240
48. Pomara G, Morelli G, Menchini-Fabris F, et al: Epistaxis after PDE-5 inhibitors misuse. Int J Impot Res 2006; 18:213-214 (Pubitemid 43336492)
49. Tzathas C, Christidou A, Ladas SD. Sildenafil (Viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol 2002; 97:1856 (Pubitemid 34761434)
50. Mourani PM, Sontag MK, Ivy D, et al: Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154:379-384
51. Humpl T, Reyes JT, Erickson S, et al: Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young 2011; 21:187-193
52. Van den Anker, JN: Managing drugs safely. Semin Fetal Neonatal Med 2005; 10:73-81
53. Simon E, Janette R, Des B, et al: Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am CollCardiol 2002; 39(Suppl 2):402
54. Namachivayam P, Theilen U, Butt WW, et al: Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174:1042-1047 (Pubitemid 44684454)
55. Raja SG, Danton MD, MacArthur KJ, et al: Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth 2007; 21:203-207 (Pubitemid 46528282)
56. Ajami GH, Borzoee M, Radvar M, et al: Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension. Pediatr Cardiol 2008; 29:552-555
57. Lee JE, Hillier SC, Knoderer CA: Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008; 23:329-334
58. Hunter L, Richens T, Davis C, et al: Sildenafil use in congenital diaphragmatic hernia. Arch Dis Child Fetal Neonatal Ed 2009; 94:F467
59. Uhm JY, Jhang WK, Park JJ, et al: Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. Pediatr Cardiol 2010; 31:515-520
60. Nemoto S, Sasaki T, Ozawa H, et al: Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. Eur J Cardiothorac Surg 2010; 38:71-77
61. Gaetano P, Raffaele G, Veronica R, et al: Sildenafil therapy for pulmonary hypertension. Clin Invest 2011; 38:238-242
62. Fraisse A, Butrous G, Taylor MB, et al: Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease: Intensive Care Med 2011; 37:502-509
63. Nyp M, Sandritter T, Poppinga N, et al: Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 2012; 32:64-69
64. Behrsin J, Cheung M, Patel N: Sildenafil weaning after discharge in infants with congenital diaphragmatic hernia. Pediatr Cardiol 2013; 21:187-193